Abstract
Background
Chemosensitivity tests have long been discussed but remain a topic of research. In this study, we investigated the correlation between the results of a chemosensitivity test for 5-fluorouracil and 5-chloro-2, 4-dihydroxypyridine and the clinical outcomes of gastric cancer patients treated with S-1, an oral fluoropyrimidine, as adjuvant chemotherapy.
Methods
For gastric cancer patients, we performed surgical treatment and a lymph node dissection of D2 or more. Afterwards, a chemosensitivity test for 5-fluorouracil and 5-chloro-2, 4-dihydroxypyridine was performed, using the collagen gel droplet embedded culture drug-sensitivity test (CD-DST), in surgical specimens. All the patients received postoperative adjuvant chemotherapy with S-1 for 1 year, and the overall survival (OS), relapse-free survival (RFS), and adverse events were investigated.
Results
The chemosensitivity test was performed for 27 patients. The growth inhibition rate (IR) was 50% or more (high-sensitivity group) in 59.3% (16 cases) and it was under 50% (low-sensitivity group) in 40.7% (11 cases). The 3-year OS rate was 100% in the high-sensitivity group and 62.34% in the low-sensitivity group. The 3-year RFS rate was 83.33% in the high-sensitivity group and 24.24% in the low-sensitivity group. Thus, the 3-year OS rate and the 3-year RFS rate were higher in the high-sensitivity group than in the low-sensitivity group. No adverse events of grade 3 or greater severity were observed.
Conclusions
The results of the chemosensitivity test were correlated with the patient outcome. Therefore, such results might be useful for individualizing cancer chemotherapy and for determining future indications for postoperative adjuvant chemotherapy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Kubota T. Individualized tumor response assay (in Japanese). Jpn J Cancer Chemother 2008;35:174–177.
Hoffman RM. In vitro sensitivity assays in cancer: a review, analysis and prognosis. J Clin Lab Anal 1991;5:133–143.
Hoffman RM. In vitro assays for chemotherapy sensitivity. Crit Rev Oncol Hematol 1993;15:99–111.
Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810–1820.
Kobayashi H. Development of a new in vitro chemosensitivity test using collagen gel droplet embedded culture and image analysis for clinical usefulness. Recent Results Cancer Res 2003;161:48–61.
Kobayashi H, Higashiyama M, Minamigawa K, Tanisaka K, Takano T, Yokouchi H, et al. Examination of in vitro chemosensitivity test using collagen gel droplet culture method with colorimetric endpoint quantification. Jpn J Cancer Res 2001;92:203–210.
Hanatani Y, Kobayashi H, Kodaira S, Takami H, Asagoe T, Kaneshiro E. An in vitro chemosensitivity test for gastric cancer using collagen gel droplet embedded culture. Oncol Rep 2000;7:1027–1033.
Mori S, Kunieda K, Sugiyama Y, Saji S. Prediction of 5-fluorouracil and cisplatin synergism for advanced gastrointestinal cancers using a collagen gel droplet embedded culture. Surg Today 2003;33:577–583.
Nakajima T, Nashimoto A, Kitamura M, Kito T, Iwanaga T, Okabayashi K, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomized trial. Lancet 1999;354:273–277.
Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, et al. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol 2003;21:2282–2287.
Kitamura M, Nakajima T, Ohta K, Nashimoto A, Yamamura Y, Furukawa H, et al. Adjuvant chemotherapy of gastric cancer: JCOG experience. New York Heidelberg Berlin Tokyo: Springer; 1999. p. 32–41.
Kinoshita T, Nakajima T, Ohashi Y. Adjuvant chemotherapy with uracil-tegafur for serosa-negative advanced gastric cancer. Results of a randomized trial by National Surgical Adjuvant Study of Gastric Cancer. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 2005;16S:4021.
Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977;197:461–463.
Von Hoff DD. He’s not going to talk about in vitro predictive assays again, is he? J Natl Cancer Inst 1990;82:96–101.
Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, et al. Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res 1995;1:1537–1543.
Saikawa Y, Kubota T, Furukawa T, Suto A, Watanabe M, Kumai K, et al. Single-cell suspension assay with an MTT end point is useful for evaluating the optimal adjuvant chemotherapy for advanced gastric cancer. Jpn J Cancer Res 1994;85:762–765.
Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture drug response assay. Clin Cancer Res 1995;1:305–311.
Fujita K, Kubota T, Matsuzaki SW, Otani Y, Watanabe M, Teramoto T, et al. Further evidence for the value of the chemo sensitivity test in deciding appropriate chemotherapy for advanced gastric cancer. Anticancer Res 1998;18:1973–1978.
Abe S, Kubota T, Matsuzaki SW, Otani Y, Watanabe M, Teramoto T, et al. Chemosensitivity test is useful in evaluating the appropriate adjuvant cancer chemotherapy for stage III non-scirrhous and scirrhous gastric cancers. Anticancer Res 1999;19:4581–4586.
Kubota T, Egawa T, Otani Y, Furukawa T, Saikawa Y, Yoshida M, et al. Cancer chemotherapy chemosensitivity testing is useful in evaluating the appropriate adjuvant cancer chemotherapy for stages III/IV gastric cancer without peritoneal dissemination. Anticancer Res 2003;23:583–587.
Nakamura R, Saikawa Y, Kubota T, Kumagai A, Kiyota T, Ohashi M, et al. Role of the MTT chemosensitivity test in the prognosis of gastric cancer patients after postoperative adjuvant chemotherapy. Anticancer Res 2006;26:1433–1437.
Iwahashi M, Nakamori M, Nakamura M, Noguchi K, Ueda K, Nakatani Y, et al. Individualized adjuvant chemotherapy guided by chemosensitivity test sequential to extended surgery for advanced gastric cancer. Anticancer Res 2005;25:3453–3460.
Kubota T, Weisenthal L. Chemotherapy sensitivity and resistance testing: to be “standard” or to be individualized, that is the question. Gastric Cancer 2006;9:82–87.
Fujita Y, Hiramatsu M, Kawai M, Nishimura H, Miyamoto A, Tanigawa N. Histoculture drug response assay predicts the postoperative prognosis of patients with esophageal cancer. Oncol Rep 2009;21:499–505.
Yamaue H, Tani M, Onishi H, Kinoshita H, Nakamori M, Yokoyama S, et al. Locoregional chemotherapy for patients with pancreatic cancer: intra-arterial adjuvant chemotherapy after pancreatectomy with portal vein resection. Pancreas 2002;25:366–372.
Kodera Y, Ito S, Fujiwara M, Mochizuki Y, Ohashi N, Ito Y, et al. In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues. Int J Clin Oncol 2006;11:449–453.
Kubota T. Individualized tumor response assay. Nippon Rinsho 2008;66:239–244.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Maejima, K., Tokunaga, A., Kiyama, T. et al. Chemosensitivity test for 5-fluorouracil and 5-chloro-2, 4-dihydroxypyridine predicts outcome of gastric cancer patients receiving S-1 postoperatively. Gastric Cancer 13, 231–237 (2010). https://doi.org/10.1007/s10120-010-0564-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10120-010-0564-1